Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Finch Therapeutics clinches $53m series C round
Microbiome drug developer Finch Therapeutics has collected investments from SymBiosis and SIG among others to push its total funding to near $95m.
Oncorus hits with series B
Existing investors Celgene and Astellas returned to back the virus-based cancer therapy developer's $79.5m series B round to take its total funding to more than $140m.
Protenus complies with corporates to raise $17m
Kaiser Permanente Ventures and Providence Ventures were among the investors that helped health data management platform Protenus take its overall funding above $35m.
10x Genomics gees up for $100m IPO
SoftBank-backed medical research technology provider 10x Genomics, valued at nearly $1.3bn as of this year, has filed to go public.
IGM Biosciences eyes public markets spot
Anti-cancer antibody developer IGM has filed to raise up to $100m, weeks after securing $102m in a Haldor Topsøe-backed series C round.
SpringWorks sparks $115m IPO filing
GlaxoSmithKline and Pfizer are in line for exits after oncology drug developer SpringWorks filed to float on the Nasdaq Global Market.
Satsuma sets course for public markets
Shin Nippon spinoff Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.
Corporate venturing deal net: 12-16 August 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Other News

Renovacor recovers $11m in series A round
Novartis Venture Fund co-led the gene therapy developer's series A round, raised as it prepares to submit an investigational new drug application for its lead drug.
Jazz carries away Cavion in $313m deal
Novartis and Eli Lilly are exiting the neurological disease therapy developer in an acquisition that will involve $52.5m upfront and up to $250m in milestone payments.
Innovaccer chases $60m investment
The M12-backed healthcare data management platform is speaking to new investors and is targeting between $50m and $60m at a $300m valuation.
Carisma dazzles with extended series A round
The company has revealed it added approximately $6m to a series A round co-led by AbbVie Ventures last year, bringing its total size to about $59m.
Oric obtains $55m in series D round
Taiho, Memorial Sloan Kettering Cancer Center and Hartford HealthCare contributed to a round that boosted the cancer drug developer's total funding to more than $175m.
Corporate venturing deal net: 5-9 August 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Editor's Picks

BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
Pfizer’s Jones to retire
Elaine Jones, vice-president at pharmaceutical company Pfizer’s corporate venture capital unit, has shared highlights of her career with GCV ahead of her departure in April.
M&A of the Year: Prexton Therapeutics
Having emerged from the Merck Serono Entrepreneur Partnership Program (EPP) in 2015, Prexton Therapeutics raised a total $41m of funding before it was acquired by pharmaceutical firm Lundbeck for an estimated $1.1bn last year.
CVC in 2018 - The Trends: Part Two
In the second half of our guide to corporate venturing's biggest trends in 2018, we look at the growth of Chinese tech companies, genomics, advances in transport tech and the growth of the scooter rental space.
test reg